[New growth hormone secretagogues: from physiology to the first therapeutic applications].
Growth hormone releasing peptides (GHRP) are synthetic hexapeptides that physiologically stimulate GH release through two different pathways: 1) central and 2) direct action on somatotropic cells. Animal experiments and first clinical trials show that synthetic GHRP and synthetic analogues could be useful substitutes to recombinant GH in the treatment of GH deficiency, and in pathological conditions which may benefit from amplification of the GH-IGF I axis activity.
Ahnfelt-Rønne
I
I
Health Care Discovery, Novo Nordisk Parc, Maalov, Danemark.
Haahr
P M
PM
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D013006:Growth Hormone / Q000172:deficiency* / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D009842:Oligopeptides / Q000502:physiology* / Q000627:therapeutic use*; D010902:Pituitary Gland / Q000187:drug effects; D051381:Rats
D009842:Oligopeptides; C041048:growth hormone releasing hexapeptide; D013006:Growth Hormone
Les nouveaux sécrétagogues de l'hormone de croissance: de la physiologie aux premières applications thérapeutiques.